![]() |
市場調查報告書
商品編碼
1725062
吹灌封設備市場預測至2032年:按產品、產能、填充量、類別、腔體數量、模具數量、容器裝飾、形狀、最終用戶和地區進行的全球分析Blow Fill Seal Equipment Market Forecasts to 2032 - Global Analysis By Product, Capacity, Filling Volume, Category, Number of Cavities, Number of Mold, Decorations of the Containers, Shape, End User and By Geography |
根據 Stratistics MRC 的數據,全球吹灌封設備市場預計在 2025 年價值 24.3 億美元,預計到 2032 年將達到 35 億美元,預測期內的複合年成長率為 5.3%。
吹灌封(BFS)設備是一種先進的無菌包裝技術,廣泛應用於製藥、保健和食品行業的液體無菌包裝。在這個自動化過程中,塑膠容器由聚合物樹脂連續成型,然後立即在無菌環境中填充和密封。透過顯著減少人工干預的需要,該技術降低了污染的可能性並提高了產品安全性。單位劑量藥物、眼藥水、呼吸道藥物和其他無菌液體產品的處理是 BFS 設備的特殊應用。更重要的是,它們能夠加快生產速度,同時保持高精度和衛生標準,這使它們成為現代無菌製造業務中的寶貴工具。
根據美國腸外藥物協會 (PDA) 的說法,吹灌封 (BFS) 技術被公認為一種先進的無菌工藝,在無菌藥物製造方面具有顯著優勢。 PDA 的技術報告第 77 號為 BFS 系統的操作提供了全面的指導,強調了它們在透過最大限度地減少填充和密封過程中的人為干預來提高產品安全性方面的作用。
藥品對無菌包裝的需求不斷增加
製藥業始終面臨遵守最嚴格的安全和衛生法規的壓力,尤其是在注射和吸入藥物方面。透過將容器成型、填充和密封整合為單一、連續、自動化的循環,BFS 機器可確保無菌填充完成程序。此外,它還大大降低了微生物污染的可能性,使其成為包裝無菌液體的理想選擇。隨著疫苗、生技藥品和特種藥品產量的增加,對無菌包裝的需求也在成長,尤其是在醫療保健基礎設施快速發展的開發中國家。
初期投資高
購買和安裝BFS設備的初始成本高是其廣泛採用的主要障礙之一。高度專業化的 BFS 機器將填充、密封和成型過程結合到一台自動化機器中。對於中小型製造商,尤其是新興國家的製造商來說,這種複雜性會增加初始投資並成為沉重的負擔。此外,公司不僅需要支付機器本身的費用,還需要支付無塵室設置、基礎設施升級和合規認證的費用,這進一步增加了整體擁有成本。
特種藥物和生技藥品製造業的成長
隨著製藥業向生技藥品、生物相似藥和個人化醫療發展,確保無菌和產品穩定性的先進包裝技術變得越來越必要。疫苗、單株抗體和細胞療法等敏感生技藥品的無菌包裝非常適合 BFS 系統。此外,隨著全球範圍內對生物製藥的核准增多,BFS 設備製造商有很大機會為高價值、小批量生產創建客製化解決方案,特別是對於需要單位劑量形式和低污染機會的利基療法。
其他無菌包裝技術的競爭加劇
儘管BFS是一種成熟的無菌技術,但它面臨著其他尖端填充系統的激烈競爭,包括成形充填密封(FFS)技術、管瓶填充線和預填充式注射器。這些替代系統通常提供更大的靈活性,特別是對於具有多樣化包裝要求的公司。預填充式注射器由於其易於使用且對患者安全有益,在注射藥物和生技藥品市場中越來越受歡迎。此外,由於製造商根據價格、格式和易用性等因素選擇這些替代品,BFS 的市場佔有率可能會下降。
COVID-19 疫情以多種方式影響了吹灌封 (BFS) 設備市場。由於危機,對無菌包裝解決方案的需求顯著增加,尤其是疫苗、呼吸道藥物和單劑量藥物。這突顯了 BFS 技術對於維持無菌和減少污染的重要性。許多製藥商加強了基於 BFS 的灌裝作業力度,以滿足緊急的醫療保健需求,這推動了對 BFS 系統的近期投資。然而,非必要產業資本投資的延遲、工業營運的限制以及全球供應鏈的中斷暫時阻礙了計劃時間表和新產能的安裝。
預計預測期內瓶裝飲料市場規模最大。
預計預測期內瓶子部分將佔據最大的市場佔有率。生產用於包裝液體製劑(例如止咳糖漿、補液溶液、眼藥水等)的各種尺寸的無菌塑膠瓶是非常適合 BFS 技術的應用。這種瓶型具有防篡改、延長保存期限和降低污染風險等優點,非常適合大量生產。此外,隨著單位劑量包裝需求的不斷成長以及向經濟實惠的無防腐劑替代品的轉變,瓶裝產品在 BFS 市場中佔據主導地位。
預計噴墨列印領域在預測期內將實現最高的複合年成長率
由於對快速、靈活且經濟實惠的標籤解決方案的需求不斷成長,預計噴墨列印領域將在預測期內呈現最高的成長率。噴墨列印具有可變資料列印、按需客製化和交貨時間短等諸多優勢,非常適合需要連續包裝和短週轉時間的製藥應用。由於監管部門越來越重視產品可追溯性、批次編碼和防偽措施,製造商開始採用噴墨列印來確保合規性並提高業務效率。此外,它與各種容器形狀和材料的兼容性使其能夠吸引更廣泛的最終使用領域。
在預測期內,北美地區預計將佔據最大的市場佔有率,這得益於其先進的製藥生產設施、嚴格的法律要求以及對無菌和密封包裝的高需求。該地區完善的醫療保健體系、慢性病的高發性以及對單劑量藥物日益成長的偏好推動了 BFS 技術的廣泛應用。為了遵守 FDA 和 USP 無菌處理法規,美國和加拿大的主要製藥公司和受託製造廠商(CMO) 正在將 BFS 系統納入其生產線。
預計亞太地區在預測期內的複合年成長率最高。這是由於中國、印度和東南亞等開發中國家醫療保健和製藥業的爆炸性擴張。醫療保健成本的上升、所需藥物的更容易獲得以及學名藥產量的增加,正在推動對具有成本效益、大容量無菌包裝解決方案的需求。此外,該地區的政府正在大力投資當地的製藥製造和醫療保健基礎設施,這可能會推動 BFS 的採用。此外,由於受託製造廠商(CMO)、法規遵循和無污染藥物輸送的成長,製藥公司正在投資 BFS 技術。
According to Stratistics MRC, the Global Blow Fill Seal Equipment Market is accounted for $2.43 billion in 2025 and is expected to reach $3.50 billion by 2032 growing at a CAGR of 5.3% during the forecast period. Blow-fill-seal (BFS) equipment is an advanced aseptic packaging technology widely used in the pharmaceutical, healthcare, and food industries for the sterile packaging of liquids. In this automated process, plastic containers are continuously formed from polymer resin, immediately filled, and sealed in a sterile environment-all in a single machine cycle. By drastically lowering the need for human intervention, the technology lowers the possibility of contamination and improves product safety. Packaging unit-dose drugs, eye solutions, respiratory treatments, and other sterile liquid products is a special application for BFS equipment. Moreover, it is a useful tool in contemporary sterile manufacturing operations because of its capacity to expedite production while maintaining high standards of precision and hygiene.
According to the Parenteral Drug Association (PDA), Blow-Fill-Seal (BFS) technology is recognized as an advanced aseptic process that offers significant advantages in sterile pharmaceutical manufacturing. In their Technical Report No. 77, the PDA provides comprehensive guidance on the operation of BFS systems, emphasizing their role in enhancing product safety by minimizing human intervention during the filling and sealing processes.
Growing pharmaceutical need for aseptic packaging
The pharmaceutical industry is constantly under pressure to uphold the strictest safety and hygienic regulations, especially with regard to injectable and inhalable drugs. By integrating container formation, filling, and sealing into a single, continuous, automated cycle, BFS equipment guarantees a sterile fill-finish procedure. Additionally, this greatly lowers the chance of microbial contamination, making it the perfect choice for packaging sterile liquids. As more vaccines, biologics, and specialty medications are produced, there is a greater need for aseptic packaging, especially in developing nations where healthcare infrastructure is developing quickly.
High initial outlay of funds
The high initial cost of buying and setting up BFS equipment is one of the main factors preventing its widespread use. Highly specialized BFS machines combine filling, sealing, and molding processes into one automated device. For small and medium-sized manufacturers, particularly those in emerging economies, this complexity raises the initial investment, which can be a major burden. Furthermore, companies must also spend money on cleanroom settings, infrastructure upgrades, and compliance certifications in addition to the machinery itself, which raises the total cost of ownership even more.
Growth in the production of specialty drugs and biologics
Advanced packaging technologies that guarantee sterility and product stability are becoming more and more necessary as the pharmaceutical industry moves toward biologics, biosimilars, and personalized medicine. Aseptic packaging of delicate biologics, including vaccines, monoclonal antibodies, and cell-based treatments, is a good fit for BFS systems. Moreover, manufacturers of BFS equipment have a significant opportunity to create customized solutions for high-value, small-batch production as a result of the global increase in biologic drug approvals, particularly for niche therapies that demand unit-dose formats and low contamination risk.
Increasing rivalry from other aseptic packaging technologies
Although BFS is a well-established aseptic technology, it is up against fierce competition from other cutting-edge fill-finish systems like form-fill-seal (FFS) technologies, vial filling lines, and prefilled syringes. These substitutes frequently provide more flexibility, particularly for businesses with a range of packaging requirements. Because of their ease of use and benefits for patient safety, prefilled syringes in particular are becoming more and more popular in the injectable drug and biologics markets. Additionally, the market share of BFS may decline if manufacturers start choosing these substitutes due to factors like price, format, or usability.
The COVID-19 pandemic affected the blow-fill-seal (BFS) equipment market in a number of ways. The need for aseptic packaging solutions was greatly increased by the crisis, particularly for vaccines, respiratory medications, and single-dose drugs. This underscored the importance of BFS technology in maintaining sterility and reducing contamination. Short-term investments in BFS systems were fuelled by a number of pharmaceutical manufacturers increasing their BFS-based fill-finish operations to meet urgent healthcare needs. However, delays in capital expenditure in non-essential sectors, limitations on industrial operations, and disruptions in global supply chains temporarily hampered project timelines and the installation of new equipment.
The bottles segment is expected to be the largest during the forecast period
The bottles segment is expected to account for the largest market share during the forecast period. The production of sterile plastic bottles in a range of sizes for the packaging of liquid formulations, including cough syrups, rehydration solutions, and eye medications, is a highly suitable application for BFS technology. The bottle format is perfect for high-volume production because it provides benefits like tamper-evidence, longer shelf life, and a lower risk of contamination. Additionally, the bottle segment's dominance in the BFS market is still supported by the rising demand for unit-dose packaging and the move toward affordable, preservative-free alternatives.
The ink-jet printed segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the ink-jet printed segment is predicted to witness the highest growth rate, driven by the growing need for high-speed, flexible, and affordable labeling solutions. With its many benefits, such as variable data printing, on-demand customization, and short turnaround times, ink-jet printing is perfect for pharmaceutical applications that call for serialized packaging and short production runs. Manufacturers are using ink-jet printing to ensure compliance and boost operational efficiency as a result of increased regulatory emphasis on product traceability, batch coding, and anti-counterfeiting measures. Furthermore, it is more appealing to a wider range of end-use sectors due to its compatibility with various container shapes and materials.
During the forecast period, the North America region is expected to hold the largest market share because of its sophisticated pharmaceutical production facilities, strict legal requirements, and high demand for sterile, impenetrable packaging. The widespread adoption of BFS technology is fueled by the region's well-established healthcare system, high prevalence of chronic diseases, and growing preference for single-dose medications. In order to comply with FDA and USP regulations for aseptic processing, major pharmaceutical companies and contract manufacturing organizations (CMOs) in the United States and Canada have incorporated BFS systems into their production lines.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by the healthcare and pharmaceutical industries' explosive expansion in developing nations like China, India, and Southeast Asia. Cost-effective, high-volume aseptic packaging solutions are in high demand due to rising healthcare costs, easier access to necessary medications, and an increase in the production of generic drugs. The region's governments are also making significant investments in local pharmaceutical production and healthcare infrastructure, which will facilitate the adoption of BFS. Additionally, pharmaceutical companies are investing in BFS technology due to the growth of contract manufacturing organizations (CMOs), regulatory compliance, and contamination-free drug delivery.
Key players in the market
Some of the key players in Blow Fill Seal Equipment Market include Gerresheimer AG, Adinath International, Robert Bosch GmbH, Serac Group, Syntegon Technology GmbH, Recipharm AB, Marchesini Group S.p.A., Brevetti Angela S.r.l., Gea Group Aktiengesellschaft, Rommelag Kunststoff-Maschinen Vertriebsgesellschaft Gmbh, Foshan Coretamp Packaging Machinery Co. Ltd, Unither Pharmaceuticals, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc and Weiler Engineering, Inc.
In July 2024, German engineering and electronics group Robert Bosch GmbH has agreed to acquire Johnson Controls International ( JCI )'s global heating, ventilation, and air-conditioning ( HVAC ) business for residential and light commercial buildings in an all-cash deal valued at US$8.1 billion.
In June 2024, Takeda announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.
In May 2024, Gerresheimer Glas, a subsidiary of Gerresheimer, has entered into a purchase agreement to acquire Blitz LuxCo, the holding company of Bormioli Pharma. The acquisition is valued at approximately €800m. Bormioli Pharma, with nine production sites across Europe, offers a range of pharmaceutical primary packaging products made from glass and plastic, including closure solutions, accessories, and dispensing systems.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.